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http://dx.doi.org/10The mouse is integral to our understanding of hematopoietic biology. Serving as a mammalian
model system, the mouse has allowed for the discovery of self-renewing multipotent stem cells,
provided functional assays to establish hematopoietic stem cell identity and function, and has
become a tool for understanding the differentiation capacity of early hematopoietic progeni-
tors. The advent of genetic technology has strengthened the use of mouse models for identi-
fying critical pathways in hematopoiesis. Full genetic knockout models, tissue-specific gene
deletion, and genetic overexpression models create a system for the dissection and identifica-
tion of critical cellular and genetic processes underlying hematopoiesis. However, the murine
model has also introduced perplexity in understanding developmental hematopoiesis. Requi-
site in utero development paired with circulation has historically made defining sites of origin
and expansion in the murine hematopoietic system challenging. However, the genetic accessi-
bility of the mouse as a mammalian system has identified key regulators of hematopoietic
development. Technological advances continue to generate extremely powerful tools that
when translated to the murine system provide refined in vivo spatial and temporal control
of genetic deletion or overexpression. Future advancements may add the ability of reversible
genetic manipulation. In this review, we describe the major contributions of the murine model
to our understanding of hematopoiesis.  2014 ISEH - International Society for Experi-
mental Hematology. Published by Elsevier Inc.
 Open access under CC BY license.Introduction
Early observations of the hematovascular system
Study of the hematopoietic system has historically been diffi-
cult because of its complexity. The majority of differentiated
blood cells exist in circulation, while the progenitors gener-
ally remain within their niche. In vertebrates, the origins of
the hematopoietic tissue are nonsingular, with a shifting
source and localization over time. In total, the hematopoietic
system is comprised of hematopoietic stem cells (HSCs),
multiple terminally differentiated lineages, and multiple in-
termediate committed progenitors. The mouse model has al-
lowed for the biological manipulation of the varied
components that comprise the hematopoietic system using
genetic approaches, transplantation, and lineage-tracing.
Initial studies seeking to define the origin of the hemato-
vascular system were performed at the turn of the century.Ann C. Zovein, MD, Cardiovascular Research Insti-
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.1016/j.exphem.2014.06.008Foremost was the work of Francis Sabin using chick hanging
drop experiments, which allowed for direct visualization of
the area pellucida as the hematovascular system was being
formed [1]. The direct observation of a population of cells
that appeared to arise from the mesoderm and were distinctly
identified by their increased granularity and refractive prop-
erties were termed ‘‘angioblasts’’ because they expanded and
comprised a vascular network [1]. After the subsequent ag-
gregation of these angioblasts, the appearance of vacuoles
was noted and thought to serve a role in the eventual appear-
ance of centralized blood cells (altogether termed blood
islands), suggesting to the observer that the hematovascular
system originated from blood-island producing angioblasts
[1]. The change from a mesodermal cell into a ‘‘stem’’ or
‘‘mother’’ cell was postulated to be the origin of the entire
hematopoietic system [2]. The blood island aggregates
were not only noted in the yolk sac but also within the major
embryonic vessels of the chick [1] as well as within mamma-
lian models including the pig, rabbit, and mouse [3]. Later
observers of this phenomenon would coin the term heman-
gioblasts when referring to the blood-island forming angio-
blasts [4]. Although many of these seminal observationsPublished by Elsevier Inc.  Open access under CC BY license.
Figure 1. Contributions to hematopoietic biology. A spiral timeline of major contributions the mouse system has made to our understanding of hematopoi-
esis. From early transplantation and clonal analyses to transgenic technology and future advancements, the mouse system has served as a critical model for
hematopoietic biology.
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quickly adopted by hematologists due to its closer evolu-
tionary relationship to humans, ease of culture and utility,
and eventually due to its genetic accessibility. Although
many of the initial observations of the hematopoietic system
were made in the early 1900s, the elucidation of blood as a
single stem cell derived lineage was not made until the 1960s
via mouse transplantation models (Fig. 1).
Transplantation
Identification and functional analysis of hematopoietic
stem cells
The postulation that the bone marrow was the seed-tissue of
the hematopoietic lineage dates back to 1866 [5]. However,
it wasn’t until our understanding of irradiation and anemia
that a test was developed to assess whether a specific site
was responsible for maintaining the hematopoietic system.
In 1951, it was noted that anemia after irradiation could be
mitigated by protecting the spleen with a lead shield [6]. In
the same year, transplantation of bone marrow cells was
demonstrated to rescue irradiation lethality in mice andguinea pigs [7]. The transplantation study was the first to
detail the use of cell suspensions, suggesting against the
possibility that previous rescue or shielding experiments
were due to a ‘‘humoral’’ factor [7]. To further the cellular
hypothesis, transplanted bone marrow from a mouse line
heterozygous for a distinct translocation demonstrated
cellular repopulation was due to cell engraftment and not
humoral factors [8]. It was demonstrated shortly thereafter
that repopulation occurs in a dose-dependent (cell number)
manner [9]. It was also demonstrated that frozen marrow
could protect against radiation lethality [10].
The first reports to recognize the existence of a HSC
comprise a landmark body of work by Till and McCulloch
[11–15], published between 1963–1964. While earlier re-
ports demonstrated the proliferative capacity of hematopoiet-
ic cells, the work of Till and McCulloch recognized the
clonal repopulating activity of bone marrow that was trans-
planted into irradiated host mice. The experiments showed
that mice that are subjected to a lethal dose of x-ray radiation
are rescued by clonal expansion of donated bone marrow
[11]. This was done by cytological analyses of spleen col-
onies that form upon transplantation. When bone marrow
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itor cells can populate the spleen and contribute to hemato-
poiesis. This assay allows for the macroscopic colonies to
be easily counted. Today it is known as the colony forming
unit-spleen (CFU-S) assay, which is a quantitative readout
for repopulating activity. It was discovered that rare cyto-
logic abnormalities could be seen in a subset of spleen col-
onies that were unique among colonies but shared among
all cells within the colony, strongly suggesting a clonal origin
of the hematopoietic colony [11]. By comparing the number
of bone marrow cells transplanted to the number of splenic
colonies, a tight correlation between the two was shown.
Following up this study, further investigations by Till and
McCulloch demonstrated the self-renewal capacity of
HSCs by serially transplanting cells from the bone marrow
and formed splenic colonies, and they showed that the col-
ony forming units decline in their ability to repopulate irra-
diated hosts after serial transplantations [12]. In 1969, the
group published their work on transplantation of bone
marrow cells after separation using sedimentation though
serum gradients. By showing that repopulating activity
peaked within a certain fraction using velocity sedimentation
to physically separate cells by size, the group highlighted the
heterogeneity of bone marrow and supported the notion of a
distinct set of stem cells [16]. This allowed for the develop-
ment of competitive repopulation assays where competing
bone marrow subsets from two separate hosts with distin-
guishable hemoglobin profiles are transplanted [17], allow-
ing for the evaluation of HSC long-term function
comparisons across mouse lines. The in vivo clonal analysis
of the CFU-S led to its in vitro derivative, the colony forming
unit-culture (CFU-C), a robust in vitro assay that is still
relied upon today for in vitro functional analysis. One of
the first clonal in vitro differentiation assays was devised
by Pluznick and Sachs in 1965, where granulocyte colonies
could be cultured and different organs could be assayed for
their ‘‘mast’’ cell content [18]. Mouse bone marrow was
then also noted to form colonies in vitro using feeder layers
[19], which proposed the existence of hematopoietic matura-
tion factors, termed ‘‘colony stimulating factors’’ [20].
A decade later, cell sorting and analysis technology ush-
ered in the identification and functional analyses of hemato-
poietic subsets. A series of landmark reports [21–24] utilized
a relatively new blend of technologiesdthe use of cell-
surface antibodies and fluorescence-activated cell sorting
with transplantation. Weissman et al [21] demonstrated that
Thy-1loLinSca-1þ cells had multilineage repopulation ca-
pacity in transplanted host animals. They provided three ma-
jor breakthroughs for the field. They described a cell-surface
antigen profile of HSC subsets, in which HSCs could be
sorted and seeded into a host, and irrefutable evidence of a
self-renewable HSC pool. They further demonstrated that
this population of bone marrow HSCs was the only popula-
tion with the capacity to rescue the host mouse, self-renew,
and repopulate the hematopoietic system of the organism[25]. The group also demonstrated the multilineage repopu-
lating capacity of the HSC subset using limiting dilution and
antigen-tracing techniques [26].
The defined HSC marker set was then expanded to include
the signaling lymphocyte activation molecule (SLAM) family
receptor CD150, discovered through gene expression
profiling of sorted HSCs [27]. Furthermore, HSCs could be
distinguished from progenitor populations through expression
of different SLAM receptors (CD150, CD244, and CD48)
[27]. The new surface marker repertoire for HSCs indicated
that there may be further refinement of markers that can
detect HSCs uniquely and that the current criteria for sorting
HSCs may be further simplified. Despite having a well-
defined marker set, it is noted that individual HSCs do not
contribute to all lineages in constant proportions. There
have been multiple reports using single-cell lineage transplan-
tation, which indicate individual HSCs isolated from bone
marrow may have distinct and unique lineage contributions
from another isolated in the same pool [28,29]. Thus, while
transplantation has allowed the identification of HSCs and
the refinement of surface markers to detect them, HSCs are
in themselves a heterogeneous population, as recently
demonstrated by single-cell clonal transplantation analysis
[30] and a new technique of cellular barcoding [31,32]. In
addition, recent studies suggest in addition to lymphoid- or
myeloid-biased HSCs [33], there may also be long term pro-
genitor populations that self-renew [30].
Developmental origin of HSCs
Many embryonic and fetal tissues have been found to contain
hematopoietic cells capable of reconstitution of irradiated
adult hosts. It was previously shown by multiple groups
that both the yolk sac and fetal liver have the capacity to pro-
duce CFU-S colonies [34,35]. As the earliest appearance of
blood cells (nucleated erythrocytes) are located in the yolk
sac blood islands, investigation into the onset of HSC devel-
opment has focused on the hematopoietic capacity of this tis-
sue. In addition, the assays used to distinguish the initial
autonomous site of hematopoiesis within the embryo were
near identical to those used in the adult murine system,
namely the transplantation of irradiated adult hosts. In
1967, Moore and Owen [36] had initially evaluated the avian
model using chromosome markers between male and female
animals and irradiated embryos to demonstrate that yolk sac
cells contributed to adult hematopoietic organs. However, it
was observed that the contributions did not account for all
the hematopoietic cells in the adult [36]. Moore and Metcalf
[35] then expanded these studies to the murine system by
transplanting yolk sac cells after 2–6 days culture, as well
as fetal liver into irradiated adult hosts. It was noted the
yolk sac after culture could reconstitute adult hosts begin-
ning at 8 days of gestation, and that the fetal liver could
begin reconstitution at day 10, which coincided with the
reconstitution ability of circulating cells of the embryo
[35]. In addition, when the 7-day embryo and yolk sac are
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reside in the yolk sac [35]. This set a paradigm where the
first HSCs were thought to derive from yolk sac blood
islands, then enter the circulation to take up residence in
the fetal liver before finally populating the adult bone
marrow.
This paradigm was challenged in 1975 by a seminal
article using avian systems by Dieterlen-Lievre [37],
whose grafting experiments of chick yolk sacs to quail em-
bryos demonstrated an intraembryonic source of the adult
hematopoietic system. However, there was a lack of support
for the model in murine systems. While the murine system
had hithertofore been the defining system for hematopoietic
ontological study, it had many drawbacks when compared
with the avian system. In utero development makes the mu-
rine embryo inaccessible to direct manipulation for subse-
quent late-stage or adult analyses. In addition, its
circulatory system connecting the embryo, yolk sac, and
placental circulation makes the discrimination between sites
of HSC origin and migration arduous. However, despite
these challenges, support for a mammalian intraembryonic
site of HSC origination was established in the early 1990s
[38,39]. The aorta, gonad, mesonephros (AGM) region was
discovered to be the intraembryonic murine hematopoietic
site analogous to that of the avian system [38]. It was demon-
strated that the murine AGM had higher CFU-S capacity
than the yolk sac or fetal liver [38], and the CFU-S activity
originates autonomously in the AGM region [39]. These
studies were then supported by the detection of lymphoid
and multilineage HSC activity in the embryonic paraaortic
splanchnopleura (the precursor to the AGM) [40,41].
Furthermore, when the yolk sac was separated from the em-
bryo before circulation, the para-aortic splanchnopleura
demonstrated lymphoid potential in vitro [42] and reconstitu-
tion capacity of irradiated adult hosts [43], suggesting that
akin to the avian species, the mammalian embryo body,
and not the yolk sac, is the source for adult HSCs.
Thus, murine developmental sites of hematopoiesis were
historically defined by long-term multilineage repopulation
capability of adult hosts. It should be mentioned however
that the heterochronic transplantation scheme has multiple
drawbacks for developmental analyses. It assumes that re-
population activity is not observed in the host mouse
because of cell-intrinsic properties, and also that the host
is competent to receive the cell population. Moreover, there
may exist HSCs in the early embryo that require maturation
in developmental niches before acquiring the capacity of
engrafting irradiated adult hosts. Using a newborn myeloa-
blation model, yolk sac cells incapable of adult engraftment
were demonstrated to be capable of long-term reconstitu-
tion in the newborn mouse [44,45]. Furthermore, it was
shown that bone marrow from these carrier pups could
then be isolated and used to reconstitute irradiated adult
mice [45]. Taken together, these results demonstrate that
the embryonic yolk sac does have the capacity for multi-lineage long-term engraftment of a host mouse. Yet when
the strict standard of reconstitution of adult hosts is applied,
the earliest embryonic site capable of adult engraftment, us-
ing in vitro culture followed by transplantation, is the intra-
embryonic para-aortic splanchnopleura/AGM. The early
yolk sac is then relegated to the source of a transient or
‘‘primitive’’ wave of hematopoiesis of erythroid progeni-
tors, but it is also noted to be the source of multiple long-
term lineages including macrophage and lymphoid
populations and, later in development, multipotent HSCs
[46]. In addition to the yolk sac, the placenta can also
contribute significantly to the definitive HSC pool, as
measured by transplantation assays [47,48]. By E10.5–
11.0, all hematopoietic regions in the embryodyolk sac,
AGM, placenta, and fetal liverdcan reconstitute adult irra-
diated hosts. But because circulation is well established at
that time, it is difficult to discern relative contributions.
When isolated before circulation at E8.0, only the para-
aortic splanchnopleura, after several days in culture, has
been shown to engraft adult hosts.
The murine system as a functional assay for human
hematopoiesis
In addition to its critical role in our current understanding
of mammalian developmental hematopoiesis and HSC
biology, mouse models have also provided an invaluable
resource in understanding human hematopoiesis by allow-
ing functional assessment of human HSCs. Termed ‘‘hu-
manized mice,’’ murine models have been established that
allow xenografts of human cells into mice. As engraftment
of human cells will not occur in standard mouse breeds due
to immunological rejection, attenuated models were devel-
oped. One of the first reports of humanized mouse models
noted that the scid/scid (Prkcdscid) mouse strain, which
lacks T and B cells and thus recapitulate severe combined
immune deficiency (SCID), can be engrafted with human
fetal thymus, liver, and lymph node cells (termed SCID-
hu mice), resulting in the detection of human lymphoid
cells within the mouse circulation [22]. The SCID-hu
model then inspired subsequent investigation into immuno-
deficient mouse strains with the aim of improving human
engraftment efficiency [49]. The most recent evolution of
the model combines the nonobese diabetic (NOD)/severe
combined immunodeficiency (SCID) strains with an
IL2R-gc chain null mutant [50,51], and hence is referred
to as the NOD/SCID IL2Rg (NOG or NSG) mouse line.
The NSG line demonstrates robust engraftment efficiency
when human cells are transplanted into newborn and adult
NSG mice [50,51]. Hence, the NSG mouse model has
become an invaluable tool for multiple fields that include
hematology, immunology, and virology (HIV has been
studied in these lines dating back to the original SCID-hu
model) [52]. The model is now considered the standard
for functional evaluation of human hematopoietic
populations.
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Murine knockout models of primitive and definitive
hematopoiesis
While the concept of ‘‘primitive’’ hematopoiesis arose
initially from morphological analyses of the first embryonic
blood cells [46], transplantation assays and the develop-
ment of transgenic mouse models refined the characteriza-
tion of primitive and definitive hematopoiesis. Expansion of
the definition suggests that ‘‘primitive’’ represents a tran-
sient population not present in the adult, while HSCs that
arise in the embryo and persist throughout adulthood are
termed ‘‘definitive’’. Knockout (KO) technology in the
mouse has enabled the study of specific genes involved in
both primitive and definitive hematopoiesis. Evaluation of
genetically engineered mice with homozygous loss of a
specific gene helps determine how that gene may function
and in which particular hematopoietic lineage. While the
list of critical genetic KO mouse models is exhaustive
and thoroughly reviewed elsewhere [53], here we focus
on a few of the key genes identified.
Early erythroid differentiation was shown to require the
transcription factor GATA1 using genetic deletion in mouse
ES cells [54]. It was demonstrated that Gata1-deficient
cells in chimeric mice were unable to contribute to the
erythroid lineage, affecting both primitive and definitive
waves of hematopoiesis [54,55]. Similarly, Gata2 knockout
mice exhibit defects in primitive hematopoiesis, and Gata2
null cells do not contribute to definitive hematopoiesis in
chimeras [56]. Both Gata1 and Gata2 knockouts result in
embryonic lethality, and the two genes functionally overlap
in primitive erythropoiesis [57]. However, Gata2 was also
found to have a critical role in HSC maintenance and
expansion [58] with gene dosage effects on HSC ontogeny
in the AGM [59]. Insight into Gata2 regulation was
recently made when GATA1 was demonstrated to bind up-
stream Gata2 locus sites, exerting a repressive role [60,61],
while genetic deletion of a cis-acting element composed of
an E-box and GATA motif proved critical for Gata2 func-
tion in the AGM [62].
A putative target of GATA2 is SCL/tal1 [63], a transcrip-
tion factor known to be expressed in hematovascular tissues
[64] that was first identified because of its translocation in
human leukemia [65]. SCL/tal-1 knockout mice die after
E10.5 with failure of yolk sac hematopoiesis [66–68].
Chimeric mice generated with scl null cells demonstrated
that SCL/tal-1 is responsible for all cell contributions to
definitive hematopoiesis, as no null cells were found within
the chimera’s hematopoietic system [66,69]. SCL became
of immense interest, as its loss of function phenotype and
its expression pattern suggested that it lie at the top of a reg-
ulatory network necessary for the early hemangioblast
specification and subsequent HSC function [70,71]. There-
fore, due to its function in both waves of hematopoiesis,
SCL was considered a panhematopoietic gene. The adventof conditional gene deletion in mice would refine this defi-
nition, and will be discussed later in this section.
Runx1, formerly known as core-binding factor alpha 2
(Cbfa2), is another transcription factor discovered through
its translocation in human leukemias, and is known as acute
myeloid leukemia gene 1 (AML1). It demonstrates severe
hematopoietic defects when deleted in vivo [72,73]. The
Runx1 knockout mouse was critical in providing evidence
of a distinct definitive wave of hematopoiesis in vivo. Total
loss of the Runx1 gene results in complete loss of definitive
hematopoiesis with little or no defect in yolk sac primitive
hematopoiesis [73,74]. Due to its substantial requirement
in definitive populations, expression patterns of Runx1
became of significant interest in developmental hematopoie-
sis. Runx1 was noted to be localized to the major arterial re-
gions of the embryo and their associated clusters of rounded
hematopoietic cells [74,75], which were described nearly a
century prior [3]. Runx1 loss ablated the formation of arterial
associated clusters [74,75]; hence, investigation ensued as to
whether the endothelium, its underlying mesenchyme, or
another population (possibly circulating hemangioblasts)
gave rise to the early appearance of definitive Runx1þ
HSCs. It would not be an answerable question in the murine
system without the development of new genetic tools that al-
lowed for dissection of gene requirements within specific tis-
sue compartments.
Compartment matters: Fate tracing, conditional, and
timed conditional knockouts
With the advent of Cre recombinase technology [76,77],
gene function within a specific tissue compartment can be
studied by expressing the bacteriophage enzyme Cre recom-
binase under the control of a tissue-specific promoter [78].
When crossed to a mouse line genetically engineered with
the gene of interest flanked by loxP sites (floxed), the floxed
gene segment is excised in tissues expressing the promoter
driven Cre [78]. This extremely powerful tool has engen-
dered groundbreaking discoveries in mammalian biology,
as it combines the detailed genetic manipulation of lower
vertebrate models with the murine in vivo mammalian sys-
tem. Furthermore, alterations of the original technology
have produced temporal genetic control via timed induction
of Cre recombinase activity [79]. Timed induction is
achieved with fusion of the Cre recombinase to a mutated es-
trogen receptor specific for synthetic estrogen analogues
(tamoxifen) but not endogenous estrogen, termed CreERT
[79–81], and a subsequent generation CreERT2 [82,83].
Another important adaptation of the Cre-Lox system is that
of cellular fate tracing. Cre activity can be used to recombine
a floxed stop codon upstream of a fluorescent reporter in a
ubiquitously constitutively expressed locus, such as the
ROSA26 locus [84], allowing for the expression of the re-
porter [85]. With conditional and inducible genetic manipu-
lation now available, multiple groups have revisited
the original knockout data with a refined evaluation of
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well as the powerful tool of genetic fate tracing.
Understanding the origination site for definitive HSCs
became possible using these powerful genetic tools in the
murine system. Because previous work demonstrated that
Runx1 was required for definitive HSCs, the Cre recombi-
nase system was then used to specifically delete Runx1 in
endothelial versus hematopoietic compartments [86,87].
Using this targeted approach, it was demonstrated that the
Runx1 requirement for HSC emergence is exclusive to the
endothelial compartment [86], lending credence to the
notion of endothelial-derived hematopoiesis, e.g. hemo-
genic endothelium. The concept of hemogenic endothelium
contrasts that of the hemangioblast, whereby the hemangio-
blast is a postulated bipotential mesodermal cell that gives
rise to endothelium and blood in parallel, and hemogenic
endothelium suggests an endothelial population specified
from the mesoderm that directly produces blood cells. It
is an important distinction when trying to understand how
definitive HSCs are specified. The requirement of Runx1
in the endothelial compartment, in addition to endothelial
fate tracing that demonstrated HSCs originate from endo-
thelial compartments [88], strongly suggest that definitive
HSCs arise directly from hemogenic endothelium. These
studies were later supported by in vitro live imaging of mu-
rine endothelium producing hematopoietic clusters [89,90].
Inducible Cre technology was also used to fate trace early
Runx1þ cells in the embryo, whereby induction of Runx1
populations via a Runx1-Cre at E7.5 demonstrated fate-
mapped lineages in the adult bone marrow [91]. Early
embryonic contributions to adult hematopoiesis were also
supported by the use of circulation mutants. Ncx/ em-
bryos lack a functional circulation and under those condi-
tions, the yolk sac, and separately the placenta, were
demonstrated to harbor definitive HSCs [92,93].
Interestingly, while Runx1 is required in endothelial pop-
ulations for HSC development [86], HSCs then later function
in a Runx1-independent fashion [87]. The stark contrast of
phenotypes between total loss of gene function, suggesting
ongoing requirements in HSCs, and conditional loss within
the hematopoietic compartment, demonstrating only very
early requirements, is not specific to Runx1. The critical he-
matopoietic transcription factor SCL/tal-1 demonstrates a
similar lack of requirement after conditional loss in the he-
matopoietic compartment [94,95]. Two groups using an
Mx-Cre to delete SCL/tal1 in hematopoietic cells [94,95],
noted a lack of any major effects on HSC function, despite
data from scl–/– chimeras suggesting an scl requirement for
all hematopoietic cells [66,69]. Using a Tie2 Cre for induc-
tion of early endothelial populations, it was noted that fetal
liver HSCs remained intact, suggesting that the requirement
for SCL/tal-1 in HSC emergence was before or during Tie2
endothelial specification in the early embryo [96]. Timed
loss of the SCL/tal-1 gene during early development (E6.5–
8.5) demonstrates that SCL serves to repress cardiogenesisin early mesoderm for specification of hemogenic endothe-
lium [97]. Thus, many of the critical transcription factors
for hematopoiesis uncovered by total gene loss seem to func-
tion very early in development. One exception is the tran-
scription factor Gata2. Gata2 tissue-specific deletion in
both endothelial and hematopoietic compartments, using a
VE-cadherin Cre and Vav-Cre respectively, demonstrates
its universal requirement for HSC emergence and survival
[98,99]. Thus much like the total loss of Gata2 function
[56], conditional studies demonstrated that Gata2 is a regu-
lator of the HSC population throughout development.
While HSCs and hematopoietic progenitor cells are
functionally assessed by transplantation and in vitro
colony-forming assays, the combination of these tools with
transgenic mouse technology has uncovered their coexis-
tence and coemergence in the embryo. For example,
CBFb/ mutants (CBFb is a Runx1 binding partner)
display significant hematopoietic defects [100]. Rescue of
mutants by expression of CBFb under the endothelial-
specific promoter Tek, or Tie2, favors the generation of
erythroid or myeloid progenitors [101]. However, CBFb
expression from the Ly6a (Sca-1) promoter, favors the
generation of bona fide HSCs [101], suggesting that the
emergence of hematopoietic progenitors and HSCs can be
uncoupled even when both populations have similar gene re-
quirements. As technological advancements are made within
the murine system, the true complexity of hematopoietic
emergence and differentiation can be further elucidated.
Conclusions
Caveats
We have touched upon the major advances in mouse
models allowing for timed- and tissue-specific deletion,
as well as the historical importance of mouse transplanta-
tion models in HSC biology. However, many of the new
advances highlighted are not without caveats. Tissue-
specific Cre induction is entirely dependent on the
promoter activity and specificity that drives the Cre re-
combinase gene. Hence when making conclusions about
fate tracing or gene function, it is crucial to account for
all populations that may activate the promoter in both
physiological and pathological states. Timed conditional
Cre models introduce an added variable of tamoxifen ki-
netics. Developmental windows of hematopoietic sites
are quite narrow as the AGM, yolk sac, placenta, and fetal
liver all have overlapping periods of HSC activity. Tamox-
ifen levels tend to peak in adult murine sera within
24 hours of administration by intraperitoneal injection
and can linger at levels shown to activate CRE-ERT in cul-
ture [80,82] for at least 48–72 hours [88]. In addition, the
efficiency of Cre recombinase to excise a particular
flanked genetic sequence also varies significantly [102].
Other models of timed gene regulation in the murine sys-
tem include the tet-on/off systems that allow for
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expression [103]. Although the inducible mouse models
differ in their regulation, they have the similar caveats
of reliance on promoters and pharmacologic agents for
control. As mentioned previously, transplantation assays
are not also without drawbacks, especially for the develop-
mental system. Early pre-HSC populations may be inca-
pable of engrafting an irradiated adult, but they may be
competent to become an adult HSC when allowed to phys-
iologically mature in its own host. In addition, adult HSC
engraftment may signify a different functional ability of
donor cells in a unique pathologic environment.Mouse models of the future
Given the caveats of the current models, it is not surprising
that newer technologies are being adapted to the mouse sys-
tem for improved genetic control. One such system that is
rapidly being adopted is the CRISPR/Cas9 genome editing
system [104–106]. The bacterial system is comprised of a
Cas9 nuclease that can be guided to a particular sequence
in the genome for the generation of mouse lines with point
mutations, deletions, conditional deletion, or reporter
expression [106], or multiplexed for manipulations of mul-
tiple genes at once [104,105]. In addition, the system can be
used for large-scale gene silencing (CRISPRi) [107–109].
While the CRISPR/Cas9 system now allows generation of
more complex genetically engineered mouse lines, it would
be ideal to harness the multiple applications of the system
for spatial and temporal control. Its current promise for
multiple genetic modifications in a single mouse line can
allow for the investigation of multiple related or unrelated
hematopoietic genes within the same organism. In addition,
human genetic mutations can be recapitulated in the murine
system to understand how a particular mutation impacts he-
matopoietic development and function in the animal.
Downstream genetic analyses of hematopoietic subsets
have also become more robust with the advent of high-
throughput sequencing. Sequencing at the single cell level
combined with genetic barcoding (the generation of
uniquely marked single cells) is an extremely powerful
tool for understanding single cell and population dynamics,
progeny, and fate. DNA barcoding allows for clonal ana-
lyses in vivo. Using retroviral libraries with unique
sequence tags (barcodes), HSCs are transduced and then
transplanted with subsequent evaluation [31,110]. While
this can only currently be done in isolated cell populations
with subsequent transduction and transplantation, one could
imagine future mouse models that may allow for tissue- or
time-specific integration of barcodes for in vivo analyses.
The murine system has allowed enormous advancement
in our understanding of hematopoiesis and HSC biology,
and with the rapid development of new technologies and
adaptation into the mouse system, it will likely serve as a
compelling model system well into the foreseeable future.References
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